Chapter 1. Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market – Scope & Methodology
1.1 Market Segmentation
1.2 Scope, Assumptions & Limitations
1.3 Research Methodology
1.4 Primary Sources
1.5 Secondary Sources
Chapter 2. Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market – Executive Summary
2.1 Market Size & Forecast – (2023 – 2030) ($M/$Bn)
2.2 Key Trends & Insights
2.2.1 Demand Side
2.2.2 Supply Side
2.3 Attractive Investment Propositions
2.4 COVID-19 Impact Analysis
Chapter 3. Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market – Competition Scenario
3.1 Market Share Analysis & Company Benchmarking
3.2 Competitive Strategy & Development Scenario
3.3 Competitive Pricing Analysis
3.4 Supplier-Distributor Analysis
Chapter 4. Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market - Entry Scenario
4.1 Regulatory Scenario
4.2 Case Studies – Key Start-ups
4.3 Customer Analysis
4.4 PESTLE Analysis
4.5 Porters Five Force Model
4.5.1 Bargaining Power of Suppliers
4.5.2 Bargaining Powers of Customers
4.5.3 Threat of New Entrants
4.5.4 Rivalry among Existing Players
4.5.5 Threat of Substitutes
Chapter 5. Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market – Landscape
5.1 Value Chain Analysis – Key Stakeholders Impact Analysis
5.2 Market Drivers
5.3 Market Restraints/Challenges
5.4 Market Opportunities
Chapter 6. Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market – By Therapy
6.1 Introduction/Key Findings
6.2 Chemotherapy
6.3 Targeted Drug Therapy
6.4 Others
6.5 Y-O-Y Growth trend Analysis By Therapy
6.6 Absolute $ Opportunity Analysis By Therapy, 2023-2030
Chapter 7. Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market – By End-User
7.1 Introduction/Key Findings
7.2 Hospitals
7.3 Homecare
7.4 Speciality Centres
7.5 Others
7.6 Y-O-Y Growth trend Analysis By End-User
7.7 Absolute $ Opportunity Analysis By End-User, 2023-2030
Chapter 8. Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market , By Geography – Market Size, Forecast, Trends & Insights
8.1 North America
8.1.1 By Country
8.1.1.1 U.S.A.
8.1.1.2 Canada
8.1.1.3 Mexico
8.1.1.4 By Therapy
8.1.2 By End-User
8.1.3 Countries & Segments - Market Attractiveness Analysis
8.2 Europe
8.2.1 By Country
8.2.1.1 U.K
8.2.1.2 Germany
8.2.1.3 France
8.2.1.4 Italy
8.2.1.5 Spain
8.2.1.6 Rest of Europe
8.2.2 By Therapy
8.2.3 By End-User
8.2.4 Countries & Segments - Market Attractiveness Analysis
8.3 Asia Pacific
8.3.1 By Country
8.3.1.1 China
8.3.1.2 Japan
8.3.1.3 South Korea
8.3.1.4 India
8.3.1.5 Australia & New Zealand
8.3.1.6 Rest of Asia-Pacific
8.3.2 By Therapy
8.3.3 By End-User
8.3.4 Countries & Segments - Market Attractiveness Analysis
8.4 South America
8.4.1 By Country
8.4.1.1 Brazil
8.4.1.2 Argentina
8.4.1.3 Colombia
8.4.1.4 Chile
8.4.1.5 Rest of South America
8.4.2 By Therapy
8.4.3 By End-User
8.4.4 Countries & Segments - Market Attractiveness Analysis
8.5 Middle East & Africa
8.5.1 By Country
8.5.1.1 United Arab Emirates (UAE)
8.5.1.2 Saudi Arabia
8.5.1.3 Qatar
8.5.1.4 Israel
8.5.1.5 South Africa
8.5.1.6 Nigeria
8.5.1.7 Kenya
8.5.1.8 Egypt
8.5.1.9 Rest of MEA
8.5.2 By Therapy
8.5.3 By End-User
8.5.4 Countries & Segments - Market Attractiveness Analysis
Chapter 9. Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market – Company Profiles – (Overview, Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market Portfolio, Financials, Strategies & Developments)
9.1 Hoffmann-La Roche AG
9.2 Novartis International AG
9.3 Merck & Co., Inc.
9.4 Pfizer Inc.
9.5 AbbVie Inc.
9.6 Eli Lilly and Company
9.7 Bristol-Myers Squibb Company
9.8 Tocagen Inc.
9.9 Kazia Therapeutics Limited
9.10 Celldex Therapeutics, Inc.
2500
4250
5250
6900
Frequently Asked Questions
The Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market was estimated at USD 2.44 Billion in 2022. Projections suggest continued growth in this market segment at a CAGR of 4.6%.
The market growth is driven by factors such as the rising incidence of glioblastoma cases, advancements in research and development, strategic partnerships, and increased healthcare investments globally.
The market is segmented into several therapeutic approaches and End-Users.
North America traditionally holds the largest market share in the Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market.
Key players operating in the Glioblastoma Multiforme Adult Malignant Glioma Therapeutics Market include Hoffmann-La Roche AG, Novartis International AG, Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Tocagen Inc., Kazia Therapeutics Limited, Celldex Therapeutics, Inc., known for their contributions to research, development, and treatment advancements in the field.